MARKETS / NASDAQ / AAPG

NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Ascentage Pharma Group International AAPG

3 fiscal years on record · CNY · FY2024 reported

SEC FILINGS ONLY

Revenue · FY2024

¥980.6M

▲ 341.8% vs FY2023

EPS · FY24

¥-1.34

Dividend / sh · FY24

—

Payout · FY24

—

ROE · FY24

-249.8%

Net margin · FY24

-41.3%

Dividend coverage

—

Result

CNY 980.6M

Revenue, FY2024 · full 3-year series below

Revenue Net income

The company lost 41 cents on every revenue dollar this year.

Per share

CNY -1.34

Diluted EPS, FY2024

EPS

The company pays no cash dividend.

Profitability

-249.8%

Return on equity, FY2024

ROE

Operating margin—

Net margin-41.3%

Return on assets—

Each CNY of equity lost 250 cents this year.

Returned to shareholders

—

returned in FY2024 · dividends + net buybacks

Dividends paid—

Net buybacks—

Share of profit—

Consecutive raises—

Growth

—

revenue, compounded over five years

CAGR

3 yrs

5 yrs

10 yrs

15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base

0.32B

Shares outstanding, FY2024

Change, 5 years—

Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Balance sheet

—

total assets, end of FY2024

EquityCNY 264.2M

CashCNY 893.1M

Gross debtCNY 1.7B

Net debtCNY 775.4M

DepositsCNY 343.5M

Current ratio1.26×

Net debt stands at 293% of equity.

History

3 fiscal years

Every figure from documents filed with the SEC · CNY

Metric

2024

2023

2022

Revenue ¥B

1.0

0.2

Operating income ¥B

EBITDA ¥B

Income tax ¥B

0.0

−0.0

Net income ¥B

−0.4

−0.9

EPS, diluted ¥

−1.34

−3.28

−3.35

Dividend / sh ¥

Payout %

ROE %

−249.8

−1532.1

Shares out B

0.32

0.29

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED

8 of 8

checks passed before publication

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed

Market capitalizationneeds a market quote — not yet licensed

Dividend yieldneeds a market quote — not yet licensed

Price-to-bookneeds a market quote — not yet licensed